ReviewHeliyon2024
Advancements in nanobiosensor technologies for in-vitro diagnostics to point of care testing.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026Review
- Biomarkers of Cancer Metabolism and Therapeutic Response.Cancer treatment and research · 2026Review
- Next-generation viral detection through AI-enhanced nanotechnology: advances, challenges, and future directions.Frontiers in molecular biosciences · 2026Article
- Functions and applications of enzymes in nucleic acid nanotechnology.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the importance of rapid testing nanosensor technologies for in-vitro diagnostics (IVD) and point-of-care testing (POCT) is being increasingly recognized. Owing to their high sensitivity and rapidity, nanosensor-based diagnostic devices are evolving into self-diagnostic tools that enable real-time in-situ analyses. These advances have become the focus of the public health control system, not only to prevent the spread of infectious diseases but also to enable the early detection of critical diseases through continuous health monitoring technologies. Current research on rapid diagnostic nanosensor technologies has focused on improving accuracy, sensitivity, rapid test systems, cost-effectiveness, and accessibility. In this review, we discuss the development of self-testing IVD technologies based on rapid diagnostic nanosensor platforms. The convergence of nanosensors and advanced materials can provide faster, more accurate, and more accessible IVD-based POCT solutions, representing an important advancement in healthcare. Here, we present nanosensor technologies for diagnosing biomarkers in in-vitro samples and improving diagnostic efficiency. Nanosensor-based self-diagnostic devices have the potential to be extended to personalized healthcare platforms, enabling the continuous monitoring of infectious diseases, cancer, and other serious issues. This review highlights the importance of research in this field to improve diagnostic efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.